Wuxi bio launches the technology platform WuXia RidGS, empowering customers to develop non-antibiotic cell lines.

Shanghai, October 28, 2024 / PRNewswire / -- China's leading contract research, development, and manufacturing organization (CRDMO) Wuxi Biologics (2269.HK) announces the launch of the WuXia RidGS cell line construction platform based on high-yield glutamine synthetase (GS) in Chinese hamster ovary (CHO) expression system. The platform serves as a non-antibiotic cell line development tool, utilizing zinc finger nuclease (ZFN) technology to knock out the endogenous GS gene in CHO cells. WuXia RidGS is derived from

PR NewswireOct 28 05:00 ET

HK Stocks Update: Pharmaceutical stocks continue to strengthen, AstraZeneca-B (01541) expands its gains in the afternoon. Hong Kong approval mechanism will be extended to all new drugs starting from November.

Pharmaceutical stocks continue to strengthen, as of the time of publication, Yimengangke-B (01541) rose by 22.76% to 7.65 Hong Kong dollars; zai lab (09688) rose by 15.25% to 25.7 Hong Kong dollars; Heyu-B (02256) rose by 8.82% to 4.32 Hong Kong dollars; tigermed (03347) rose by 11.65% to 41.2 Hong Kong dollars; wuxi bio (02269) rose by 6.68% to 17.56 Hong Kong dollars.

Zhitong FinanceOct 25 02:11 ET

Trending Industry Today: TIGERMED Leads Gains In CRO Stocks

Moomoo NewsOct 25 01:30 ET

Wuxi Bio [02269] is now trading at 17.3 Hong Kong dollars, with a rise of 5.10%.

As of 10:50, Wuxi Bio [02269] reported a share price of 17.3 Hong Kong dollars, up 0.84 Hong Kong dollars or 5.10% from the previous closing price of 16.46 Hong Kong dollars, with a turnover of 458.7831 million Hong Kong dollars. The highest price today is 17.3 Hong Kong dollars, and the lowest price is 16.42 Hong Kong dollars. Based on the closing price from yesterday, the 10-day average price is 16.49 Hong Kong dollars, the 50-day average price is 13.77 Hong Kong dollars, and the current PE ratio is 18.29 times. The 14-day relative strength index is reported as 42.09.

Golden Guardian Financial NewsOct 24 22:50 ET

Hong Kong stocks abnormal | The concept of CRO rose sharply in early trading, with intensive support policies for innovative drugs coming out, and the Fed may cut interest rates again in November.

Early concept of CRO rose in the morning session, as of the deadline, Frontage (01521) rose 8.45%, closing at 0.77 Hong Kong dollars; Tigermed (03347) rose 5.28%, closing at 38.85 Hong Kong dollars; Asymchem Laboratories (06821) rose 5.16%, closing at 57.1 Hong Kong dollars; Pharmaron (03759) rose 4.56%, closing at 15.6 Hong Kong dollars; Wuxi Bio (02269) rose 3.77%, closing at 17.08 Hong Kong dollars.

Zhitong FinanceOct 24 22:39 ET

Hong Kong stock market anomaly | CRO concept stocks are all rebounding, with many stocks rising by more than 10%. The National Medical Products Administration has deployed a pilot reform of segmented production of biological products.

CRO concept stocks are all rebounding, as of the time of publication, frontage (01521) rose by 14%, to 0.57 Hong Kong dollars; pharmaron (03759) rose by 12.59%, to 14.84 Hong Kong dollars; tigermed (03347) rose by 11.11%, to 38 Hong Kong dollars; wuxi bio (02269) rose by 10.54%, to 16.78 Hong Kong dollars.

Zhitong FinanceOct 18 02:41 ET